Entity Details

Primary name PURA_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionQ00577
EntryNamePURA_HUMAN
FullNameTranscriptional activator protein Pur-alpha
TaxID9606
Evidenceevidence at protein level
Length322
SequenceStatuscomplete
DateCreated1995-11-01
DateModified2021-06-02

Ontological Relatives

GenesPURA

GO terms

Show/Hide Table
GOName
GO:0000122 negative regulation of transcription by RNA polymerase II
GO:0000781 chromosome, telomeric region
GO:0000900 translation repressor activity, mRNA regulatory element binding
GO:0000977 RNA polymerase II transcription regulatory region sequence-specific DNA binding
GO:0000981 DNA-binding transcription factor activity, RNA polymerase II-specific
GO:0003691 double-stranded telomeric DNA binding
GO:0003697 single-stranded DNA binding
GO:0003723 RNA binding
GO:0005634 nucleus
GO:0006268 DNA unwinding involved in DNA replication
GO:0006270 DNA replication initiation
GO:0006357 regulation of transcription by RNA polymerase II
GO:0007399 nervous system development
GO:0008134 transcription factor binding
GO:0008284 positive regulation of cell population proliferation
GO:0030154 cell differentiation
GO:0032422 purine-rich negative regulatory element binding
GO:0032839 dendrite cytoplasm
GO:0043025 neuronal cell body
GO:0046332 SMAD binding
GO:0046651 lymphocyte proliferation
GO:0050673 epithelial cell proliferation
GO:0098794 postsynapse
GO:0098963 dendritic transport of messenger ribonucleoprotein complex
GO:0098978 glutamatergic synapse

Subcellular Location

Show/Hide Table
Subcellular Location
Nucleus

Domains

Show/Hide Table
DomainNameCategoryType
IPR006628 Purine-rich element binding protein familyFamilyFamily
IPR030500 Purine-rich element-binding protein alphaFamilyFamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
616158 OMIMMental retardation, autosomal dominant 31 (MRD31)A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD31 patients manifest neonatal hypotonia, encephalopathy with or without epilepsy, and severe developmental delay. The disease is caused by variants affecting the gene represented in this entry.